Argenta
London, United Kingdom
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (6)
○ EMA GMP
○ MHRA GMP
Quick Facts: Argenta
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- London, United Kingdom
- Modalities
- Sterile Fill-Finish (Animal Health), Non-Sterile Liquids and Pastes (Animal Health), Oral Solid Dose (Animal Health), Formulation Development (Animal Health), Pharmaceutical Development (CRO/CDMO), Monoclonal Antibodies (Animal Health), Stem Cell Therapies (Animal Health), Regulatory Affairs, Preclinical & Clinical Research (Animal Health)
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Argenta
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesSterile Fill-Finish (Animal Health), Non-Sterile Liquids and Pastes (Animal Health), Oral Solid Dose (Animal Health), Formulation Development (Animal Health), Pharmaceutical Development (CRO/CDMO), Monoclonal Antibodies (Animal Health), Stem Cell Therapies (Animal Health), Regulatory Affairs, Preclinical & Clinical Research (Animal Health)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (9 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press6 articles
Broad modality coverage (9 modalities)
Recent News 6 articles
KKR to acquire animal health firm Argenta for about $100 million - Reuters
US: Argenta acquires Shawnee sterile fill-finish manufacturing site dedicated to animal health - Investors in Healthcare
Argenta Enters $30 Million Product Financing Agreement with NovaQuest to Accelerate New Veterinary Product Development - Business Wire
Argenta Global settles into Shawnee manufacturing site after fall acquisition - The Business Journals
Scientists see cure for colorblindness - The Arkansas Democrat-Gazette
Argenta and Prelude Partner to Provide Animal Health Industry Best-in-Class Data Management Software and Support - PR Newswire
Frequently Asked Questions About Argenta
What is Argenta's CDMO Signal Score?
Argenta has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Argenta for a manufacturing program?
Use the free AI matchmaker to compare Argenta against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.